Highlights Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Delayed London S.E. Other stock markets 08:08:02 2024-06-06 am EDT			5-day change	1st Jan Change
41.52 ^GBX	+1.26%		-3.45%	-64.36%

May. 23	Windward wins deal; Kodal progresses at Bougouni	AN
May. 23	Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Windward wins deal; Kodal progresses at Bougouni	May. 23	AN
Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial	May. 23	CI
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	Apr. 30	AN
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	Apr. 09	CI
Avacta doses third patient in drug conjugate trial for tumour tissue	Mar. 21	AN
Avacta shareholders give AGM go-ahead to issue new shares	Mar. 18	AN
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	Mar. 05	AN
Avacta increases placing size to GBP26 million thanks to strong demand	Feb. 29	AN
AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise	Feb. 29	AN
Avacta plans fundraise to fund clinical development	Feb. 28	AN
Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study	Dec. 13	CI
Avacta loss widens on cost rise but clinical tests positive	23-09-28	AN
Earnings Flash (AVCT.L) AVACTA GROUP Reports H1 Revenue GBP11.9M	23-09-28	MT
Earnings Flash (AVCT.L) AVACTA GROUP Posts H1 Loss GBX-4.28	23-09-28	MT
Avacta Group Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Capital inks contract; Lansdowne becomes cash shell	23-09-20	AN
Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation	23-09-19	CI
Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study	23-06-21	CI
Avacta sees shares rise on new equity payment for South Korea venture	23-06-05	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Highlights

Filters